-
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines. -
RAF709, a novel and efficacious RAF inhibitor, activates the MAPK pathway and shows antitumor activity in tumor cells harboring BRAF or RAS mutations. -
AZD5991, a macrocyclic molecule with high selectivity for Mcl-1, reduces Mcl-1 protein in AZD5991-sensitive but not in AZD5991-resistant MM cell lines. -
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy. -
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a SMDC under development for the treatment of solid tumours.
Categories
Diseases
Others
Archives
- March 2023 (14)
- February 2023 (18)
- January 2023 (14)
- December 2022 (21)
- November 2022 (14)
- October 2022 (16)
- September 2022 (13)
- August 2022 (13)
- July 2022 (12)
- June 2022 (12)
- May 2022 (13)
- April 2022 (10)
- March 2022 (9)
- February 2022 (8)
- January 2022 (14)
- December 2021 (13)
- November 2021 (13)
- October 2021 (13)
- September 2021 (11)
- August 2021 (17)
- July 2021 (19)
- June 2021 (18)
- May 2021 (18)
- April 2021 (17)
- March 2021 (19)
- February 2021 (16)
- January 2021 (20)
- December 2020 (16)
- November 2020 (16)
- October 2020 (17)
- September 2020 (18)
- August 2020 (17)
- July 2020 (18)
- June 2020 (17)
- May 2020 (17)
- April 2020 (18)
- March 2020 (17)
- February 2020 (14)
- January 2020 (16)
- December 2019 (19)
- November 2019 (15)
- October 2019 (17)
- September 2019 (28)
- August 2019 (31)
- July 2019 (31)
- June 2019 (32)
- May 2019 (31)
- April 2019 (32)
- March 2019 (7)
